Israeli researchers make ‘significant progress’ in coronavirus vaccine

The institute's director told Prime Minister Benjamin Netanyahu that the vaccine was being readied for testing in animals. MIGAL researchers working vigorously to find a new coronavirus vaccine (photo credit: LIOR JOURNO) The Israel Institute for Biological Research (IIBR) has begun testing a COVID-19 vaccine prototype on rodents at its bio-chemical defense laboratory, a source told…

The institute’s director told Prime Minister Benjamin Netanyahu that the vaccine was being readied for testing in animals.

MIGAL researchers working vigorously to find a new coronavirus vaccine (photo credit: LIOR JOURNO)

MIGAL researchers working vigorously to find a new coronavirus vaccine

(photo credit: LIOR JOURNO)

The Israel Institute for Biological Research (IIBR) has begun testing a COVID-19 vaccine prototype on rodents at its bio-chemical defense laboratory, a source told Reuters on Tuesday.

Prime Minister Benjamin Netanyahu ordered the IIBR, in rural Ness Ziona, to join the fight against the coronavirus pandemic on Feb. 1, prompting an easing of its secrecy as it cooperates with civilian scientists and private firms.

In a statement, Netanyahu’s office said IIBR director Shmuel Shapira had informed him of “significant progress” in designing a vaccine prototype and that the institute “is now preparing a model for commencing an animal trial.”

A source familiar with IIBR activities told Reuters that trials were already under way on rodents. The source declined to identify the kind of rodent.

In rare public comments, IIBR chief innovation officer Eran Zahavy said last week that the institute had shifted its entire focus to the new coronavirus, with three groups trying to develop a vaccine against the COVID-19 disease it causes, and others researching potential treatments.

“We are trying as much as we can to collaborate and have other ideas of other people,” he said at last week’s English-language online conference hosted by Jerusalem Venture Partners.

“But the facility of the lab is very crowded and very busy and very dangerous so it has to be very slow and very cautious.”

Zahavy described arranging an animal test-subject as “a very big challenge” because “this disease is not affecting animals.”

Shapiro added that many experiments that are successful in animals are not always successful when tested on human test subjects.

“It’s not enough only to detect neutralizing antibodies in the animal. You really want to see them getting sick and getting better by this vaccine,” he said.

The IIBR has a “unique animal” for such tests, he said, as well as “a very unique technology to detect animals – even if they are not really sick – to follow them and see their interaction with the disease.” He did not elaborate.

The IIBR is also involved in plasma collection from people who have recovered from infection with the new coronavirus, in the hope that this might help research.

Israeli Defense Minister Naftali Bennett said the IIBR was sampling several COVID-19 testing kits on offer before the country orders them en masse.

Other promising research on vaccines by Israeli scientists include several emergency projects at labs at Technion-Israel Institute of Technology in Haifa, as well as the MIGAL – Galilee Research Institute in Kiryat Shmona.

Multiple labs abroad are also hard at work on finding a vaccine, including CanSino Biologics in China; Moderna and INOVIO Pharmaceuticals in the US; and CureVac and BioNTech in Germany.

Eytan Halon contributed to this report.

Read More